Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas

Emad - Elquza, Hani M. Babiker, Krisha J. Howell, Andrew I. Kovoor, Thomas David Brown, Hitendra Patel, Steven A. Malangone, Mitesh J. Borad, Tomislav Dragovich

Research output: Contribution to journalArticle

Abstract

ABSTRACT: Purpose: To establish the maximum tolerated dose (MTD) and safety profile of bi-weekly Pemetrexed (PEM) when combined with weekly cisplatin (CDDP) and standard dose external beam radiation (EBRT) in patients with locally advanced or metastatic esophageal and gastroesophageal junction (GEJ) carcinomas. Methods: We conducted an open label, single institution, phase I dose escalation study designed to evaluate up to 15–35 patients with advanced or metastatic esophageal and GEJ carcinomas. Results: 10 patients were treated with bi-weekly PEM, weekly CDDP, and EBRT. The MTD of bi-weekly PEM was determined to be 500 mg/m2.

Original languageEnglish (US)
Pages (from-to)57-63
Number of pages7
JournalCancer Investigation
Volume34
Issue number2
DOIs
StatePublished - Feb 7 2016

Fingerprint

Pemetrexed
Esophagogastric Junction
Cisplatin
Radiotherapy
Maximum Tolerated Dose
Carcinoma
Radiation
Safety

Keywords

  • cisplatin
  • gastroesophageal carcinoma
  • Pemetrexed
  • radiation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas. / Elquza, Emad -; Babiker, Hani M.; Howell, Krisha J.; Kovoor, Andrew I.; Brown, Thomas David; Patel, Hitendra; Malangone, Steven A.; Borad, Mitesh J.; Dragovich, Tomislav.

In: Cancer Investigation, Vol. 34, No. 2, 07.02.2016, p. 57-63.

Research output: Contribution to journalArticle

Elquza, Emad - ; Babiker, Hani M. ; Howell, Krisha J. ; Kovoor, Andrew I. ; Brown, Thomas David ; Patel, Hitendra ; Malangone, Steven A. ; Borad, Mitesh J. ; Dragovich, Tomislav. / Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas. In: Cancer Investigation. 2016 ; Vol. 34, No. 2. pp. 57-63.
@article{372afc6d5b7146e681c10c87c6f03067,
title = "Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas",
abstract = "ABSTRACT: Purpose: To establish the maximum tolerated dose (MTD) and safety profile of bi-weekly Pemetrexed (PEM) when combined with weekly cisplatin (CDDP) and standard dose external beam radiation (EBRT) in patients with locally advanced or metastatic esophageal and gastroesophageal junction (GEJ) carcinomas. Methods: We conducted an open label, single institution, phase I dose escalation study designed to evaluate up to 15–35 patients with advanced or metastatic esophageal and GEJ carcinomas. Results: 10 patients were treated with bi-weekly PEM, weekly CDDP, and EBRT. The MTD of bi-weekly PEM was determined to be 500 mg/m2.",
keywords = "cisplatin, gastroesophageal carcinoma, Pemetrexed, radiation",
author = "Elquza, {Emad -} and Babiker, {Hani M.} and Howell, {Krisha J.} and Kovoor, {Andrew I.} and Brown, {Thomas David} and Hitendra Patel and Malangone, {Steven A.} and Borad, {Mitesh J.} and Tomislav Dragovich",
year = "2016",
month = "2",
day = "7",
doi = "10.3109/07357907.2015.1108426",
language = "English (US)",
volume = "34",
pages = "57--63",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas

AU - Elquza, Emad -

AU - Babiker, Hani M.

AU - Howell, Krisha J.

AU - Kovoor, Andrew I.

AU - Brown, Thomas David

AU - Patel, Hitendra

AU - Malangone, Steven A.

AU - Borad, Mitesh J.

AU - Dragovich, Tomislav

PY - 2016/2/7

Y1 - 2016/2/7

N2 - ABSTRACT: Purpose: To establish the maximum tolerated dose (MTD) and safety profile of bi-weekly Pemetrexed (PEM) when combined with weekly cisplatin (CDDP) and standard dose external beam radiation (EBRT) in patients with locally advanced or metastatic esophageal and gastroesophageal junction (GEJ) carcinomas. Methods: We conducted an open label, single institution, phase I dose escalation study designed to evaluate up to 15–35 patients with advanced or metastatic esophageal and GEJ carcinomas. Results: 10 patients were treated with bi-weekly PEM, weekly CDDP, and EBRT. The MTD of bi-weekly PEM was determined to be 500 mg/m2.

AB - ABSTRACT: Purpose: To establish the maximum tolerated dose (MTD) and safety profile of bi-weekly Pemetrexed (PEM) when combined with weekly cisplatin (CDDP) and standard dose external beam radiation (EBRT) in patients with locally advanced or metastatic esophageal and gastroesophageal junction (GEJ) carcinomas. Methods: We conducted an open label, single institution, phase I dose escalation study designed to evaluate up to 15–35 patients with advanced or metastatic esophageal and GEJ carcinomas. Results: 10 patients were treated with bi-weekly PEM, weekly CDDP, and EBRT. The MTD of bi-weekly PEM was determined to be 500 mg/m2.

KW - cisplatin

KW - gastroesophageal carcinoma

KW - Pemetrexed

KW - radiation

UR - http://www.scopus.com/inward/record.url?scp=84977463111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977463111&partnerID=8YFLogxK

U2 - 10.3109/07357907.2015.1108426

DO - 10.3109/07357907.2015.1108426

M3 - Article

VL - 34

SP - 57

EP - 63

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 2

ER -